MedAdvisor Eyes $42M Sale of ANZ Business with Big Software Player

• Non-binding Letter of Intent signed with a subsidiary of a multinational software giant
• Headline sale price of $35 million plus an uncapped three-year earn-out estimated at $7.35 million
• Transaction subject to due diligence, regulatory approvals, and binding documentation
• Exclusivity granted for due diligence with a $1 million break fee under certain conditions